Rybelsus is Ozempic in a Pill. Is It Just as Good?

  • Post author:
  • Post category:uncategorized

This content originally appeared here. Republished with permission.

Medically Reviewed by Sean Hashmi, MD

People can’t stop talking about semaglutide (Ozempic, Wegovy), the buzzy diabetes and weight loss drug. Ozempic and Wegovy are injectable medications: Users prick themselves with a preloaded syringe once per week. But while the popularity of Ozempic has led to shortages, there’s been much less hype for Rybelsus, an oral form of semaglutide — the exact same drug.

What Is Rybelsus?

Rybelsus is essentially Ozempic in the form of a pill rather than an injection. Ozempic and Rybelsus are made by the same manufacturer, Novo Nordisk, and have the same active ingredient, semaglutide.[1] Semaglutide, when sold under the brand name Ozempic, is intended for people with type 2 diabetes. The same drug is also sold as Wegovy for the treatment of obesity.

Semaglutide is a GLP-1 receptor agonist, a type of drug that mimics the effect of a hormone that stimulates insulin secretion and prompts feelings of fullness. Semaglutide was originally developed and approved to treat type 2 diabetes, and it remains a powerful glucose-lowering therapy, it also has a profound effect on body weight. Many semaglutide users find themselves losing weight without having to consciously cut calories.[2]

Rybelsus is the only approved oral form of semaglutide. It’s a daily pill, and it has been shown to result in clinically significant weight loss and blood sugar improvements, both alone and in combination with other diabetes drugs.[3]

Is Rybelsus as Effective as Ozempic?

Rybelsus appears to be just as potent as Ozempic, but there’s a catch: It is only available in smaller doses.

According to the U.S. Food and Drug Administration (FDA), the maximum 14 milligram (mg) daily dose of Rybelsus is equivalent to the 0.5 mg weekly starter dose of Ozempic — one can be switched for the other without the need for a dose adjustment.[4] (Rybelsus uses higher amounts of semaglutide than Ozempic, because only a fraction of the semaglutide that enters the stomach is properly absorbed.)[5]

Clinical trials show that the two doses have a comparable metabolic effect: [6]

Rybelsus 14 mg daily pillOzempic 0.5 mg weekly injection

1.3 percentage point drop in A1C1.3 percentage point drop in A1C

10 pounds weight loss9.5 pounds weight loss

A study of real-world data found similar results: Oral semaglutide demonstrated “similar effectiveness” to injectable semaglutide.[7]

While these results suggest that Rybelsus and Ozempic could be similarly effective for people with type 2 diabetes, the two drugs are not equivalent, practically speaking, because Ozempic is available in more powerful dosages.

Ozempic is additionally available in 1 and 2 mg doses. The maximum dose, when tested in people with type 2 diabetes using metformin, led to an A1C drop of 2.2 percentage points, and weight loss of 15 pounds.[8] Rybelsus can’t match these results — at least not at the approved doses. Wegovy is available in an even higher dose, 2.4 mg per week.

Higher Doses of Rybelsus Are On The Way

In the coming years, higher doses of Rybelsus may become available. In 2023, Novo Nordisk announced that it would seek FDA approval for larger doses of oral semaglutide for the treatment of type 2 diabetes.[9]

The PIONEER PLUS trial, which tested two experimental larger doses of oral semaglutide in people with type 2 diabetes, demonstrated that at the highest dose of 50 mg, the drug’s glucose-lowering and weight loss results were at least as good as those found in Ozempic 2 mg. Study participants had an A1C reduction of 2 percentage points, and weight loss of about 20 pounds.[10][11]

Is Rybelsus Approved for Weight Loss?

Oral semaglutide is not yet approved as a weight loss therapy.

In the recent OASIS 1 trial, however, researchers tested the effect of a 50 mg dose of oral semaglutide for people who were overweight or had obesity.[12] After using the drug for over one year, study participants lost an average of 15.1 percent of their total body weight. That amount of weight loss was about equal to that achieved by people using the maximum dose of injectable semaglutide, suggesting that an oral semaglutide weight loss pill could be just as effective as the injectable.[13]

Novo Nordisk has already applied for regulatory approval for a semaglutide weight loss pill in both the United States and Europe.[14]

In the meantime, some doctors are prescribing Rybelsus off-label as a weight loss therapy for people without diabetes, especially those who cannot tolerate Wegovy or who are unable to use needles.

How to Take Rybelsus

If there’s another reason that Rybelsus hasn’t quite caught on, it’s that taking the drug is arguably something of a hassle.

According to the instructions on the FDA label, you need to take Rybelsus on an empty stomach, every morning, 30 minutes before eating, drinking, or using any other oral medications. You may have up to 4 ounces of plain water only during this time. If you have your breakfast too early, the pill will be less effective. But if you wait longer than 30 minutes to eat, the pill’s absorption may be enhanced (which could also lead to more significant side effects).

By contrast, Ozempic is a single weekly injection and can be taken at any time of day, with or without meals.

Rybelsus and Side Effects

A substantial minority of Ozempic users experience gastrointestinal side effects.[15] For some, the nausea, vomiting, or diarrhea subsides as the body gets acclimated to the drug. But others don’t feel better and end up quitting the drug entirely.

Clinical trials suggest that Rybelsus has similar side effects. A roughly similar proportion of Rybelsus study participants reported experiencing the most common side effects, including nausea, abdominal pain, diarrhea, and vomiting.

Rybelsus’ FDA label also warns of some of the same rare, serious side effects as Ozempic, including pancreatitis (inflammation of the pancreas) and acute kidney injury (a sudden decrease in kidney function).[4]

Compounded Oral Semaglutide

Some online compounding pharmacies are now advertising “oral semaglutide,” but some of these products are not, in fact, equivalent to Rybelsus. These semaglutide pills are taken sublingually (dissolved under the tongue) rather than swallowed, and therefore have an entirely different mechanism for absorption.

Buyers should be wary of such products, as there has never been any published study of sublingual semaglutide, and the safety and efficacy of such substances may be questionable.

The Takeaway

Rybelsus, an oral form of semaglutide, appears to be just as effective as Ozempic and Wegovy for diabetes management and weight loss, but it is only available in less powerful doses. In the coming years, larger doses for the treatment of both diabetes and obesity may become available. In the meantime, Rybelsus remains an effective therapy for type 2 diabetes, and may be especially useful for people with needle phobia or those who cannot take Ozempic for any other reason.

Resources We Trust

Mayo Clinic: What Happens if You Take Too Much Semaglutide?
DiaTribe: Rybelsus Now First-Line Therapy for Type 2 Diabetes
Cleveland Clinic: Oral Diabetes Medications
Harvard Health: Two Tricks to Make It Easier to Swallow Pills
Scientific American: You Quit Ozempic or Wegovy. What Happens Next?

Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.

Sources

Isaacs DM, et al. Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach. Diabetes Spectrum. February 1, 2021.
Astrup A. Reflections on the Discovery GLP-1 as a Satiety hHormone: Implications for Obesity Therapy and Future Directions. European Journal of Clinical Nutrition. July 2024.
Kalra S, Das S, Zargar AH. A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form. Indian Journal of Endocrinology and Metabolism. 2022.
Rybelsus — Highlights of Prescribing Information. U.S. Food and Drug Administration. April 2021.
Kim JC, Park EJ, Na DH. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. Pharmaceuticals. December 19, 2022.
Rodbard HW, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. October 7, 2019.
Klobucar S, Belancic A, Bukša I, et al. Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia. Diabetology. February 2, 2024.
Frías JP, et al. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg Versus 1.0 mg in Patients With Type 2 Diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, Phase 3B Trial. The Lancet Diabetes & Endocrinology. September 2021.
Novo’s High-Dose Rybelsus Win Tees up Regulatory Filings—and New Rivalries. Fierce Pharma. March 27, 2023.
Aroda VR, et al. Efficacy and Safety of Once-Daily Oral Semaglutide 25 mg and 50 mg Compared With 14 mg in Adults With Type 2 Diabetes (PIONEER PLUE): A Multicentre, Randomised, Phase 3b Trial. The Lancet. August 26, 2023.
Oral Semaglutide 25 mg and 50 mg Demonstrate Superior Reductions in HbA1C and Body Weight Versus 14 mg in People With Type 2 Diabetes in the PIONEER PLUS Phase 3 Trial. Novo Nordisk. March 24, 2023.
Knop FK, et al. Oral Semaglutide 50 mg Taken Once per Day in Adults With Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet. August 26, 2023.
Wilding JP, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. March 18, 2021.
Novo Nordisk A/S: Oral Semaglutide 50 mg Achieved 15.1% Weight Loss (17.4% if All People Adhered to Treatment) in Adults With Obesity or Overweight in the OASIS 1 Trial. Novo Nordisk. May 22, 2023.
Ozempic — Highlights of Prescribing Information. United States Food and Drug Administration. September 2023.